CIK 0001157601 · Large accelerated filer
MADRIGAL PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- MDGL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (267) 824-2827
- Business address
- 1001 CONSHOHOCKEN STATE ROAD, SUITE 2-350, WEST CONSHOHOCKEN, PA
- Former names
- MADRIGAL PHARMACEUTICALS, INC., SYNTA PHARMACEUTICALS CORP
- 4 Open-market buy Director bought 64,350 shares at an average $188.47 ($12,128,340)
- 4 Open-market buy Director bought 67,079 shares at an average $178.11 ($11,947,280)
- 4 Open-market buy Director bought 49,387 shares at an average $158.13 ($7,809,559)
- 4 Open-market buy Director bought 107,499 shares at an average $146.99 ($15,801,021)
- 4 Derivatives Options or other derivatives
- 4 Grant or award President and CEO acquired 50,000 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Grant or award Director acquired 1,198 shares (grant or award)
- 4 Grant or award Director acquired 1,198 shares (grant or award)
- 4 Grant or award Director acquired 1,198 shares (grant or award)
- 4 Grant or award Director acquired 1,198 shares (grant or award)
- 4 Grant or award Director acquired 9,584 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Senior VP, Chief Pharma Dev. sold 10,000 shares at an average $273.24 ($2,732,438)
- 4 Open-market sale Director sold 22,489 shares at an average $293.15 ($6,592,686)
- 4 Grant or award Chief Commercial Officer acquired 15,001 shares (grant or award)
- 4 Grant or award Senior VP, Chief Pharma Dev. acquired 5,667 shares (grant or award)
- 4 Grant or award SVP and General Counsel acquired 15,001 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 15,001 shares (grant or award)
Page 8 of 29 · 564 filings